CD8b Antibody [H35-17.2] (PE)

Product Specifications

Background

The H35-17.2 monoclonal antibody specifically reacts the mouse cd8 beta, a 32 kDa chain also known as Ly-3 and Lyt-3. CD8 is a T cell surface antigen co-receptor that interacts with MHC class I molecules on antigen presenting cells. It is expressed as a heterodimer with the alpha cd8 chain. The H35-17.2 antibody blocks T cell-mediated cytolysis of allogeneic lymphoma cells.

NCBI Gene ID

12526

Swiss Prot

P10300

Host

Rat

Reactivity

Mouse

Clonality

Monoclonal

Clone

H35-17.2

Conjugation

Type

Primary Antibodies

Field of Research

Immunology

Purification

The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C and should be protected from prolonged exposure to light. Do not freeze.

Fragment

Rat IgG2b, kappa

Specificity

The H35-17.2 monoclonal antibody specifically reacts the mouse cd8 beta, a 32 kDa chain also known as Ly-3 and Lyt-3.

Symbol

Cd8b1

NCBI Official Name

CD8 antigen, beta chain 1

NCBI Organism

Mus musculus

Background Reference 01

Driessens, M. H., Van Hulten, P., Zuurbier, A., La Riviere, G., Roos, E. (1996) . Inhibition and stimulation of LFA-1 and Mac-1 functions by antibodies against murine CD18. Evidence that the LFA-1 binding sites for ICAM-1, -2, and-3 are distinct.Journal of leukocyte biology,60 (6), 758-765.

Background Reference 02

Zahalka, M. A., Naor, D. (1994) . -beta-2-lntegrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness.International immunology,6 (6), 917-924.

Background Reference 03

Isobe, M., Yagita, H., Okumura, K., Ihara, A. (1992) . Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1.Science,255 (5048), 1125-1127.